东宝生物(300239) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the period reached ¥92,121,615.41, reflecting a growth of 14.70% year-on-year[9] - Net profit attributable to shareholders was ¥6,004,834.15, marking a significant increase of 74.75% compared to the same period last year[9] - The net profit after deducting non-recurring gains and losses was ¥5,455,022.34, up 106.95% year-on-year[9] - Basic earnings per share rose to ¥0.0129, an increase of 72.00% compared to the same period last year[9] - The weighted average return on net assets was 0.82%, up from 0.34% in the previous year[9] - The company's operating revenue for Q3 2018 was CNY 322,296,512.05, an increase of 32.89% compared to CNY 242,527,130.13 in the same period last year[23] - Net profit for the third quarter was CNY 4,454,080.01, up 29% from CNY 3,442,673.87 year-over-year[58] - Basic and diluted earnings per share increased to CNY 0.0096 from CNY 0.0075, reflecting a growth of 28%[58] - The net profit for Q3 2018 was CNY 21,123,998.79, an increase of 34.5% compared to CNY 15,677,175.63 in the same period last year[65] - Operating profit for Q3 2018 reached CNY 25,198,515.31, up from CNY 18,542,981.59, reflecting a growth of 36.0% year-over-year[65] Assets and Liabilities - Total assets increased to ¥1,128,510,188.44, a rise of 16.16% compared to the end of the previous year[9] - Cash and cash equivalents increased by 87.80% to ¥102,131,267.51, primarily due to increased sales revenue from gelatin, calcium hydrogen phosphate, and collagen products, as well as a loan of ¥37.5 million from a shareholder[22] - Total current assets increased to 435,668,829.51 yuan from 312,850,730.42 yuan, reflecting a significant growth in liquidity[44] - Total liabilities increased to 388,350,166.34 yuan from 241,780,572.75 yuan, showing a rise in the company's financial obligations[46] - The company's total assets reached 1,128,510,188.44 yuan, up from 971,535,396.60 yuan, indicating overall growth in asset base[46] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥18,228,225.75, a substantial increase of 174.53%[9] - Cash received from sales of goods and services increased by 50.96% to CNY 182,697,338.26, driven by higher sales of gelatin and calcium hydrogen phosphate products[26] - Cash flow from operating activities generated a net amount of CNY 18,228,225.75, a significant recovery from a net outflow of CNY 24,456,863.38 in the previous year[66] - Financing activities generated a net cash inflow of CNY 35,350,255.93, a recovery from a net outflow of CNY 7,210,742.66 in the same period last year[72] Investments and Projects - Long-term equity investments increased by 73.43% to ¥6,944,110.37, reflecting investments in raw material base construction according to the company's overall strategic plan[22] - The company plans to continue expanding its production capacity and investing in new technologies to enhance its market position[20] - The company plans to expand its production capacity from 3,500 tons to 7,000 tons of new process gelatin as part of its non-public stock issuance plan approved by the China Securities Regulatory Commission[28] - The company has received approval for its non-public stock issuance, with a total fundraising target of CNY 36,526.58 million to support its expansion projects[29] - The company is expanding its gelatin production capacity from 3,500 tons to 7,000 tons, with construction nearing completion and equipment installation in the commissioning phase[31] - The collagen project is progressing, with the main construction of the production workshop completed and major equipment being ordered[31] Government Subsidies - The company received government subsidies totaling ¥2,394,868.17, primarily related to asset-related government grants[10] - The company received government subsidies of ¥8.8 million related to assets during the reporting period[22] - The company was awarded 5 million yuan in major special funds for science and technology from the autonomous region[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 20,723[13] - The largest shareholder, Inner Mongolia Dongbao Trade Co., Ltd., holds 32.14% of the shares, totaling 149,143,800 shares[13] - The total number of restricted shares for executives and other shareholders amounted to 19,067,768 shares, with a three-year unlocking schedule[18] - Cash dividends of 13,826,223.24 yuan were distributed as part of the 2017 profit distribution plan, aligning with the company's dividend policy and shareholder meeting resolutions[38] Inventory and Costs - Inventory rose by 35.28% to ¥209,399,263.71, mainly due to the increase in products, semi-finished products, and finished products following the commissioning of the Binhe New District construction project[22] - Operating costs amounted to ¥85,881,267.45, up from ¥77,174,472.95, indicating an increase of about 11.0%[51] - The company reported a significant increase in inventory stock due to the implementation of an equity incentive plan, totaling CNY 8,455,200.00[23] Research and Development - Research and development expenses were ¥2,095,477.85, down from ¥2,584,482.31, indicating a decrease of about 18.9%[51] - Research and development expenses for the quarter were CNY 5,519,916.44, slightly up from CNY 5,004,085.36 year-over-year[60] Other Financial Metrics - Financial expenses surged by 1267.18% to CNY 1,755,562.62, primarily due to increased bank loans and corresponding interest expenses[23] - The company reported a 100% decrease in investment income, with no income generated from idle funds in the current period[23] - The company recorded investment income of CNY 7.07, a significant decrease from CNY 303,453.69 in the previous year[60] Audit and Future Outlook - The report for Q3 2018 was not audited, indicating that the figures may be subject to change upon final review[73] - Future outlook and strategic initiatives were not detailed in the provided content, suggesting a focus on current performance metrics[60]